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Abstract 
Background: STAT1 and IRF1 collaborate to induce interferon‑γ (IFNγ) stimulated genes (ISGs), but the extent to 
which they act alone or together is unclear. The effect of single nucleotide polymorphisms (SNPs) on in vivo binding is 
also largely unknown.
Results: We show that IRF1 binds at proximal or distant ISG sites twice as often as STAT1, increasing to sixfold at the 
MHC class I locus. STAT1 almost always bound with IRF1, while most IRF1 binding events were isolated. Dual bind‑
ing sites at remote or proximal enhancers distinguished ISGs that were responsive to IFNγ versus cell‑specific resist‑
ant ISGs, which showed fewer and mainly single binding events. Surprisingly, inducibility in one cell type predicted 
ISG‑responsiveness in other cells. Several dbSNPs overlapped with STAT1 and IRF1 binding motifs, and we developed 
methodology to rapidly assess their effects. We show that in silico prediction of SNP effects accurately reflects altered 
binding both in vitro and in vivo.
Conclusions: These data reveal broad cooperation between STAT1 and IRF1, explain cell type specific differences in 
ISG‑responsiveness, and identify genetic variants that may participate in the pathogenesis of immune disorders.
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provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
IFNγ is a pleiotropic cytokine that plays essential roles in 
antiviral and anticancer immune responses (reviewed in 
[1, 2]). IFNγ binds to its receptor complex and activates 
receptor-associated JAK kinases, which phosphorylate 
a substantial fraction of cytoplasmic signal transducer 
and activator of transcription 1 (STAT1). Phosphorylated 
STAT1 forms homodimers that translocate to the nucleus 
and bind IFNγ activation sites (GAS). STAT1 recruits 
histone acetyltransferases (HATs) and other transcrip-
tional co-activators to acetylate chromatin and facilitate 
transcription. Genomic studies showed that STAT1 binds 
at promoter proximal and distal sites, suggesting a role in 
remote gene regulation [3–6]. Indeed, IFNγ induces long 
range interactions between STAT1-bound enhancers and 
target promoters [7–9].
Interferon regulatory factor 1 (IRF1) is a primary target 
gene of STAT1. Like STAT1, IRF1 also acts as a transcrip-
tion factor (TF), binding to IRF-E motifs and interferon-
stimulated response elements (ISRE) [10, 11]. Access of 
both STAT1 and IRF1 to target enhancers requires the 
SWI/SNF chromatin remodeling complex to counter 
PRC2, which uses the histone methyl transferase EZH2 
to deposit H3K27me3 and block the induction of many 
other cytokine and cytokine responsive loci [7, 12, 13]. 
IRF1 functions at the transcription initiation level by 
facilitating RNA Pol II recruitment to ISGs promot-
ers [14, 15]. IRF1 also binds to remote enhancers of the 
CIITA locus that loop together to form a 3D intercon-
nected hub with the promoter [7]. Indeed, ChIP-chip 
and ChIP-seq studies show that IRF1 binds many remote 
enhancers [6, 16–18], and analysis of 128 transcrip-
tion factors in K562 cells revealed that STAT1-IRF1 co-
binding is a recurring pattern in IFNγ treated cells [19]. 
Notably, STAT1 is essential but not sufficient for gene 
induction [11], and both STAT1 and IRF1 are required 
for the IFNγ-induced expression of CIITA, GBP1, and 
gp19 [14, 15, 20]. In addition, STAT1 complexes with 
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IRF1 at the LMP2 promoter and maintains its constitu-
tive expression [21].
Here, we studied the extent of STAT1 and IRF1 coop-
eration in HeLa cells within ISG-rich chromosomal seg-
ments encompassing  ~10% of all known ISGs. Most of 
these loci responded to IFNγ in HeLa cells, leaving ~20% 
resistant ISGs. IRF1 binding sites outnumbered STAT1 
sites 2 to 1. A large fraction of STAT1/IRF1 binding 
occurred at remote sites and looping studies confirmed 
the functional role of putative enhancers at the SOCS1 
locus. Most STAT1 binding occurred at or near to IRF1 
sites (dual binding), but IRF1 often bound isolated from 
STAT1. Dual STAT1 and IRF1 but not isolated IRF1 or 
STAT1 binding was linked to ISG responsiveness. Finally, 
several variants affecting STAT1/IRF1 motifs induce or 
impair binding.
Results
Diverse gene responses to IFNγ
To define patterns of TF binding around ISGs, we 
employed tiling arrays to focus on 16  Mb distributed 
across 11 distinct chromosomal segments with a high 
density of ISGs (Fig. 1a, Additional file 1: Table S1). Nine 
segments were 1  Mb genomic regions on six chromo-
somes centered on specific IFNγ target genes (e.g. 1 Mb 
around IRF1 etc.). Two others included a 2  Mb seg-
ment centered on CIITA, and a 5 Mb segment covering 
the complete classical 3.6  Mb MHC locus and an addi-
tional 1.4  Mb 5′ region including much of the so-called 
extended MHC class I region (Fig.  1a; Additional file  1: 
Table S1). Within these regions 25% (95/375) of the genes 
are known ISGs,  ~5×  more than the genome-wide ISG 
frequency (1167/24996 ISGs) and  ~15-fold above the 
average ISGs density per Mb. The total number of Ref-
seq genes and UCSC Known Genes in the 16 Mb regions 
is 394 (Additional file  1: Table  S1). Of these, 95% (375) 
were represented on the Illumina-12 Human WG-6v3 
array used to assess gene expression (see below). The fre-
quency of Refseq genes across the genome is ~6/Mb, but 
most of the 11 chromosomal segments in our study were 
gene dense (average 24/Mb), especially at the MHC (35/
Mb), PSME (39/Mb) and IFITM clusters (45/Mb) (Addi-
tional file  1: Table  S1). There are also 126 pseudogenes 
across the 16  Mb, with most (93) located at the MHC 
cluster (Additional file 1: Table S1). Pseudogenes are not 
represented on the Illumina genome wide array we used 
to study expression.
Signaling pathway target loci show cell-specific respon-
siveness, but the exact TF binding patterns that distin-
guish induction versus resistance in a specific cell type 
are unclear. Thus, we compared the pattern of STAT1 and 
IRF1 binding at different gene types. For this we com-
piled a database of ~ all known ISGs using our own and 
prior transcriptome data (Additional file 1: Table S2). As 
summarized in Fig. 1b, ISGs fell into 8 classes depending 
on whether IFNγ caused induction, no effect (resistant 
ISGs in HeLa cells), or repression, and whether induc-
tion/repression were early (detected at 6 h) or late (24 or 
48  h), and strong (differential score ≥13, and ≥twofold 
change) or weak (differential score ≥13,  <twofold). The 
microarray expression data was validated using reverse 
transcription and quantitative PCR (RT-qPCR), which 
confirmed 83% (20/24) of indISGs and 87% (21/24) of 
resISGs (Fig. 1c). Of all 95 known ISGs on the array, 31 
(33%) genes were es-indISGs, 15 (16%) were ls-indISGs, 
29 (31%) were ew-indISGs or lw-indISGs, and 20 were 
resISGs (Fig. 1b). Es-indISGs were distributed at an aver-
age density of 1.9/Mb within the studied regions (Addi-
tional file 1: Table S1). The highest density was observed 
at the IFIT and GBP clusters with an average of 4.0 
es-indISGs/Mb.
No genes were repressed (IFNγ repressed genes, IRGs) 
at the early 6 h time point, while 19 and 23 were strongly 
or weakly repressed at later times, respectively (ls-IRGs 
and lw-IRGs; Fig.  1b), suggesting indirect regulation of 
IRGs (perhaps through activation of a repressor). The 
remaining genes that were not IFNγ-responsive either 
in this or any prior study were termed “Other Genes”. 
In summary, known ISGs fall into induced and resist-
ant subclasses in HeLa cells, providing a useful system 
to define STAT1 and IRF1 binding patterns linked to 
responsiveness.
Validation of STAT1 and IRF1 ChIP‑chip analyses
ChIP-chip was used to locate STAT1 and IRF1 sites at 
promoter proximal and distal sites of the genes of each 
category. STAT1 and IRF1 ChIPs were performed on 
chromatin from HeLa cells that were either untreated 
or exposed to IFNγ for 6  h. Hybridization intensities 
were normalized to internal standards and values from 
quadruplicate spots were averaged. Significantly dif-
ferent intensities between ChIP DNA and input DNA 
samples in three biological replicates (p  <  0.0001) were 
determined using the Wilcoxon rank sum test. Peaks 
representing the significantly enriched DNA regions 
(p  <  0.0001) where the ratio of ChIP to input DNA 
was  ≥  1.5-fold were visualized in the UCSC browser 
and plotted on a log2 scale. Only 2 STAT1 and 28 IRF1 
peaks were identified in untreated cells, rising to 92 and 
196 post-IFNγ treatment, respectively. Browser views are 
shown in Additional file 2: Figure S1 and can be visual-
ized at http://research.lunenfeld.ca/IFNy. ChIP-qPCR 
validated 91% (20/22) and 96% (23/24) of STAT1 and 
IRF1 ChIP-chip peaks, respectively (Fig. 2). We compared 
STAT1 binding at 6  h (this study) with IFNγ-induced 
STAT1 binding after 30 min [22], also assessed in HeLa 
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cells. In the 16 Mb of DNA assessed here, the latter study 
detected 26 STAT1 sites, of which 21 overlapped with the 
92 STAT1 sites we detected.
Basal TF binding
Unphosphorylated STAT1 has roles in regulating ISGs 
days after IFN treatment [23, 24], but its role in untreated 
cells is less clear, although STAT1 nuclear cytoplasmic 
shuttling occurs even in untreated cells [25–27]. Basal 
STAT1 binding is linked to the nuclear localization of 
unphosphorylated STAT1 and contributes to the con-
stitutive expression of some targets [21, 28]. IRF1 is also 
expressed to low levels in unstimulated HeLa cells [7] and 
it cooperates with STAT1 to maintain low basal expression 
levels of LMP2 [21]. In addition, there is also some STAT1 
phosphorylation (below detectable levels) in untreated 
cells that contributes to basal activity, as shown elegantly 
by knockin studies in mice [29]. We detected 2 STAT1 and 
28 IRF1 binding sites in untreated cells, accounting for 2.2 
and 14.3% of induced sites, respectively. Our data accords 
with another ChIP-chip analysis of STAT1 binding which 
reported that 6.5% of IFNγ-induced STAT1 sites in HeLa 
cells treated for 30 min with IFNγ (as opposed to 6 h in our 
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Fig. 1 IFNγ target subclasses. a Human chromosome ideograms, drawn using NCBI Map Viewer, show locations of the 11 studied chromosomal 
segments (red arrows). b The 382 genes within these regions were classified as “IFNγ stimulated genes” (ISGs), “IFNγ‑repressed genes” (IRGs) or “other 
genes” according to our expression array data and on prior studies (see “Methods” and “Results” sections for details). Known ISGs (in this and other 
studies) were either induced (indISGs) or resistant (resISGs) in HeLa cells. Genes were further subcategorized according to their robustness (strong/
weak) and timing (early/late) of induction/repression (e.g. early strong induced ISGs: es‑indISGs). Other genes were termed “not‑linked to IFNγ”, or 
“potential ISGs” (potISGs) if they were either ISG paralogs or exhibited IFNγ‑induced TF binding at their promoter. Italics indicate the number of CIITA 
targets in each class. c To validate array data, mRNA was isolated from HeLa cells left untreated or exposed to IFNγ for 6 h. RT‑PCR was performed 
on 24 induced (IndISGs) or resistant (ResISGs) ISGs, selected based on array data 6 h after IFNγ treatment. Pie diagram shows the percentage of 
validated genes
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Further analysis suggests that basal TF binding detected 
here is physiologically relevant. Of the genes with basal 
STAT1 or IRF1 binding, we assessed 21 by microarray 
and/or RT-PCR and all were expressed in untreated cells 
(Additional file 1: Table S3). In contrast, of 26 randomly 
selected ISGs that lacked basal TF binding, only 13 were 
basally expressed. Indeed, constitutive expression of 
PSMB9 and TAP2 requires constitutive IRF1 binding 
[21, 30]. In addition, several loci with basal TF binding 
are in paralogous gene clusters suggesting conservation 
of high affinity binding sites during gene duplication (e.g. 
PSMB8 and PSMB9, GBP2 and GBP3, and IFIT1, IFIT2 
and IFIT3). A high fraction (82%) of the 28 IRF1 basally 
occupied sites possessed IRF1 binding motifs. Thus, our 
data supports the notion that basal binding of STAT1 and 
IRF1 is physiologically relevant.
Remote IFNγ activated enhancers are common at ISGs
In IFNγ treated cells, 54% (50/92) of STAT1 and 44% 
(87/196) of IRF1 peaks were within 5  kb of the tran-
scription start site (TSS) of all 394 Known Genes on the 
array (Fig. 3a; Additional file 1: Table S4). Adding other 
databases, including predicted genes, raised the fraction 
to 64% for STAT1 and 57% for IRF1 (Additional file  2: 
Figure  S2A). Of equal numbers of randomly generated 
sites, the proportion at <5 kb from gene starts was much 
lower (Fig. 3a; Additional file 2: Figure S2A). Thus STAT1 
binding is slightly skewed to promoter proximal sites, 
while IRF1 binding is slightly biased toward remote sites 
(Fig. 3b).
Prior analysis of chromatin modification and looping 
at CIITA, and partial looping analysis at 1 locus support 
the idea that remote sites are functionally important [7, 
8]. To further test this notion we performed additional 
assessment of SOCS1, a key negative regulator of IFNγ 
signaling that is responsive to IFNs and other immune 
signaling pathways [31, 32]. SOCS1 responds to IFNγ 
in HeLa cells (Fig. 4a). ChIP-chip data exposed 6 IFNγ-
induced STAT1 and/or IRF1 peaks  ±  100  kb of the 
SOCS1 TSS (Fig. 4b). ChIP-qPCR analysis verified bind-
ing at the SOCS1 promoter (pSOCS1; −0.1  kb), and at 
+50, +15, −3, −55, −68 and −72 kb (Fig. 4c). A negative 
region at −63 kb was also validated. In favor of functional 
relevance of proximal and remote sites, we detected con-
stitutive histone H3 acetylation (H3ac) and/or H4ac at 
pSOCS1 (−0.1  kb), −3 and −55  kb (Fig.  4c), and IFNγ 
induced acetylation at pSOCS1 and the 6 remote sites 
but not at the irrelevant −63 kb site (Fig. 4c). These con-
stitutive and inducible events paralleled recruitment 
of the HATs CBP and/or p300 (Fig.  4c). H3K4me2 also 
marks enhancers [33], and constitutive H3K4me2 was 
detected at pSOCS1, −3  kb, −55  kb, matching consti-
tute histone acetylation, and also at the −72 kb enhancer 
(Fig. 4c), which contacts the promoter (see below). IFNγ 
treatment did not further increase methylation at these 
sites, but did induce H3K4me2 at +50  kb, +15  kb and 
−72 kb (Fig. 4c). Finally, we detected constitutive Pol II 
recruitment at pSOCS1 and −55 kb but not at the other 
TF binding or negative control sites (Fig. 4c). After IFNγ 
treatment, Pol II recruitment increased at pSOCS1, 
55% 36%
False peaks
True peaks (- GAS motif)








True peaks (- IRF-E motif)
True peaks (+ IRF-E motif)
Fig. 2 STAT1 and IRF1 binding patterns. Arbitrarily selected ChIP‑chip 
STAT1 (n = 22), IRF1 (n = 24) sites were re‑examined by ChIP‑qPCR 
on chromatin from HeLa cells with no or 6 h of IFNγ treatment. 91% 
of peaks were validated in both cases. The frequency of consensus 
motifs identified by JASPER within STAT1 (GAS) or IRF1 (IRF‑E) peaks 
is indicated
b










Fig. 3 Proximal vs. distal STAT1 and IRF1 binding. a The percentage of IFNγ‑induced STAT1 or IRF1 binding sites (top) or randomly generated con‑
trols at proximal (≤5 kb) or distal (>5 kb) sites relative to the TSS of Known genes. b IRF1 to STAT1 ratio at proximal and remote sites
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+15 kb and −55 kb (Fig. 4c). Association with the +15 kb 
element may reflect IFNγ-induced promoter looping (see 
below).
Chromosome conformation capture (3C) revealed both 
constitutive and IFNγ-induced contacts between the pro-
moter and remote STAT1 and/or IRF1 sites at CIITA [7]. 
To examine looping at SOCS1, we studied six EcoRI (I–
VI) or four NcoI (VII–X) fragments (Fig. 5a). Of a total 
of 22 possible interactions, we studied 4 previously ([8]; 
underlined in Fig. 5b) and assessed an additional 7 in this 
study. As expected, no interaction was observed between 
fragments containing the promoter and irrelevant sites at 
−63, −6, or +70 kb, either before or after cytokine expo-
sure. However, between suspected functional elements, 
we detected a total of 3 loops of all 11 putative inter-
actions in the basal state, and each of these loops was 
enhanced after IFNγ treatment and was accompanied by 
a new interaction between the +50 and −72 kb enhanc-
ers that lie 122  kb apart (Fig.  5b, c). Our data suggest 
that the SOCS1 locus is basally present in a mega loop-
ing complex that becomes more compact and involves 
more inter-element interactions after IFNγ treatment. 
Together, the ChIP and 3C data show that STAT1 and 
IRF1 binding is linked to extensive chromatin modifica-
tions and looping.
Unusual IRF1 distribution at MHC loci
As noted earlier, IRF1 exceeded STAT1 sites by ~twofold, 
but this varied at some regions, most notably at the MHC 
class I locus where the ratio was 3.5:1 (56 IRF1:16 STAT1 
sites; Additional file 1: Table S4). The ratio was particu-
larly skewed at the extended (6:1) versus classic (2.9:1) 
MHC class I region. 26 of all MHC class I IRF1 sites were 
within 5  kb of Known Gene starts and 17 within 5  kb 
of pseudogenes (Additional file  1: Tables  S4, S5), giving 
a total of 77% (43/56) promoter proximal sites, which is 
higher than the 44% at all loci (Fig. 3a; Additional file 1: 
Table  S4). However, whereas 66% (25/38) of IRF1 sites 
were promoter-proximal in the classical MHC class I 
region, this dropped to only 6% (1/18) at the extended 
MHC class I region, and was low even after including 
pseudogenes (4/18; Additional file 1: Tables S4, S5), leav-
ing an unusually high fraction of remote IRF1 sites (78%). 
Thus, IRF1 seems to play a broader role than STAT1 at 
the MHC class I cluster, primarily at proximal elements 
in the classic region, but at remote elements in the 
extended region.
STAT1 and IRF1 induce CIITA, the master regulator 
of MHC class II expression (reviewed in [34]). The num-
ber of STAT1 and IRF1 sites was typically very low in the 
MHC class II region (Additional file 1: Table S4). Out of 
13 MHC class II genes, 5 (DRB5, DQB1, DQB2, DQA2, 
and DOA) were resistant to IFNγ in HeLa cells, 5 (DOB, 
DRB1, DQA1, DPA1, DPB1) responded only after 24 h, a 
time of maximum production of CIITA [35], and 3 (DRA, 
DMB and DMA) were es-indISGS. With the exception of 
DOB, none of the resistant or late-induced genes exhib-
ited STAT1 or IRF1 promoter binding. However, of the 
3 es-indISGs, two had promoter proximal IRF1 binding 
while DMA had IRF1 binding fairly near (~8 kb) its pro-
moter. Thus IRF1 may cooperate with CIITA at a subset 
of MHC class II promoters. Others reported CIITA-inde-
pendent induction of MHC class II genes [36–39], which 
may, therefore, involve IRF1.
STAT1 and IRF1 binding is enriched at robustly induced 
ISGs
As discussed, ISGs fell into 8 classes depending on 
whether IFNγ caused induction, no effect (resistant 
ISGs in HeLa cells), or repression, and whether induc-
tion/repression were early or late, and strong or weak 
(Fig. 1b). We plotted the distribution of STAT1 and IRF1 
(See figure on next page.) 
Fig. 5 Basal and IFNγ‑induced looping at SOCS1. a A schematic view of the SOCS1 locus. Circles indicate the SOCS1 promoter (purple), putative 
remote enhancers (red), and negative control sites (blue), with distances from the TSS (red arrow) indicated above in kb, while fragments used in 
3C assays with primers (black arrowheads) are shown below. b Cross linking frequencies between the promoter and remote sites across the SOCS1 
locus. Quantitative 3C was performed with chromatin from HeLa cells left untreated or exposed to IFNγ for 6 h. Bar graphs show the crosslinking 
frequency of a selected number of interactions. Underlined interactions were published previously [8]. Marked interactions (*, †, ‡) are significantly 
different at the indicated comparisons (p < 0.05, ANOVA followed by Fisher test, mean ± SD, n = 3). c Summary of looping events. Interacting sites 
and DNA strands are colored as in a. STAT1/IRF1 (green/red dots) and Hac/H3K4me2 (green/gray diamonds; data from Fig. 6c) are also depicted
(See figure on previous page.) 
Fig. 4 STAT1 and IRF1 binding at SOCS1. a RT‑qPCR for SOCS1 mRNA in HeLa cells treated with IFNγ for 0 or 6 h. Data are in arbitrary units relative to 
β‑actin levels (log scale). b ChIP‑chip maps of STAT1 and IRF1 binding across the SOCS1 locus treated as in a. Black arrowheads indicate TF binding 
sites of interest, with distances from the TSS (red arrow) in kb. The TF‑free −63 kb site (blue) is used as a negative control in c. c ChIP‑qPCR analysis of 
the basal and IFNγ‑induced histone modifications or recruitment of the indicated factors. Marks (*, †, ‡) show significant differences (p < 0.05, ANOVA 
followed by Fisher test) in the indicated comparisons (mean ± SD, n = 3)
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binding sites relative to all 8 gene classes. Binding sites 
were assigned to the nearest gene class, designated as 
proximal or distal when ≤5 or >5 kb from the TSS, respec-
tively, and were compared to 288 randomly chosen sites 
equaling number of STAT1 + IRF1 sites (Fig. 6a). We also 
calculated the TF enrichment ratio (TER) in which the % 
distribution of TFs at proximal and distal locations was 
normalized to the % distribution of random sites (Fig. 6b). 
A binding frequency twice that of random sites (TER = 2) 
was assigned as an arbitrary minimum threshold.
STAT1 and IRF1 binding sites were most highly asso-
ciated with robustly induced IFNγ targets (es-indISGs; 
Fig.  6). This applied when STAT1 or IRF1 were consid-
ered together, separately, and at proximal or remote 
locations (Fig.  6b). Consistent with this finding, weakly 
induced genes (ew-indISGs) had fewer binding events 
and lower TERs (Fig.  6). Of 236 Other genes (never 
classified as an ISG in any study), a total of only 17 had 
9 STAT1 and 16 IRF1 proximal peaks, mostly (13/17) 
located at the MHC and RT-qPCR confirmed no induc-
tion at 10/10 of these genes (Additional file 1: Table S6). 
IFNγ enhancers loop over large distances at CIITA [7] 
and SOCS1 (Fig.  5), so proximal and distal enhancers 
nearest to Other Genes may target neighboring ISGs. 
In summary, the data indicate a clear bias of STAT1 and 
IRF1 binding at rapidly and robustly induced ISGs, but 
not other gene classes.
Isolated or dual STAT1 and IRF1 recruitment is directed 
by binding motifs
Next we compared the fraction of isolated or dual 
















































































































































Fig. 6 Enrichment of STAT/IRF1 at strong early induced ISGs. a Histogram shows the percent of STAT1, IRF1, or an equal number of randomly 
generated sites at proximal (<5 kb) or distal (>5 kb) sites of ISGs (excluding CIITA target genes), IRGs, and other genes. The number of sites in each 
category is indicated below each bar. “Random frequency”: distribution of 288 randomly generated sites. b Distribution of TFs normalized to that of 
random controls. Unshaded region indicates TER > twofold
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TF binding regions, 16% (36/230) exhibited STAT1 bind-
ing alone (isolated STAT1), of which almost half (17/36) 
were proximal; 61% (140/230) exhibited only IRF1 bind-
ing (isolated IRF1), of which 42% (59/140) were proximal; 
and 23% (54/230) showed overlap (dual STAT1/IRF1), 
of which slightly more than half (31/54) were proximal 
(Additional file  1: Table  S4). Randomly generated sites 
showed negligible overlap (Additional file 2: Figure S2B), 
but dual STAT1/IRF1 binding represented more than 
half (54/92; 59%) of all STAT1 sites and about a quarter 
(54/196; 28%) of IRF1 peaks (Fig. 7a). Fewer overlapping 
IRF1 peaks reflect their twofold excess relative to STAT1 
peaks. Thus, STAT1 preferentially binds with IRF1 at 
IFNγ enhancers, whereas most IRF1 sites are not co-
localized with STAT1.
JASPER analysis of IRF1 and STAT1 peak regions 
revealed that the cognate binding motif was observed at 
a statistically significant level relative to equal numbers of 
random peaks (Fig. 7b). 60% of isolated STAT1 peaks had 
a STAT1 motif, and only 30% had an IRF1 motif, while 
70% of isolated IRF1 peaks possessed an IRF1 motif, 
but only 20% had a STAT1 motif. A strong correlation 
existed between STAT1/IRF1 binding and the presence 
of the corresponding motifs (Fig. 7c). Indeed 40% of dual 
STAT1/IRF1 sites had both binding motifs, whereas there 
were none at equal numbers of randomly generated sites 
(Fig.  7b). Dual sites which have only a STAT1 or IRF1 
binding motif may reflect protein–protein interaction 
or DNA looping as seen at the SOCS1 and CIITA loci 
(Fig.  4c) [7, 8]. In summary, DNA sequence directs iso-
lated or dual STAT1/IRF1 binding in IFNγ treated cells.
Dual STAT1 and IRF1 targeted enhancers distinguish 
responsive from resistant ISGs
Comparing inducible ISGs in our array study with  ~all 
known ISGs in a large database (Additional file  1: 
Table  S2) revealed resistant ISGs (res-ISGs) in HeLa 
cells (Fig.  1b). There were far fewer STAT1/IRF1 bind-
ing events at res-ISGs vs ind-ISGs, and the TER (ratio 
of actual TF binding to random sites) at res-ISGs was 
low, and similar to that at other genes (Fig. 6). There was 
near ubiquitous association of both STAT1 and IRF1 at 
es-indISG promoters, but they were virtually absent at 
res-ISG promoters (Fig.  6). To quantify the types of TF 
binding events (isolated, dual, etc.), we plotted the fre-
quency of genes with at least one binding event within 
or beyond 5  kb (Fig.  8b), and the density of each type 
of binding event per gene (Fig.  8c). Isolated TF binding 
did not discriminate the two gene classes, whereas there 
was significantly more dual STAT1 and IRF1 binding at 
esISGs, at both proximal and distal sites (Fig. 8b, c). Thus, 
cooperation between STAT1 and IRF1 plays a central role 
in mediating IFNγ responsiveness.
Degree of TF binding and responsiveness in HeLa predicts 
ISG responsiveness in other cell types
Many studies have analyzed IFN-gene responsiveness, 
but a comprehensive analysis of which ISGs show broad 
or cell-type specific expression and, more importantly, 
the mechanism underlying such variability, has not been 
attempted. To assess variability in ISG induction, we com-
piled expression data on ISGs from 7 different human 
cell lines or primary cells, including 5 listed in Additional 
file  1: Table  S2, plus HeLa cells (this work) and BRG1-
reconstituted SW13 cells [13]. Across all 7 cell lines there 
were a total of 312 ISGs, the majority (61%) were exclu-
sively induced in only one cell type, 28% were induced in 
2–4 cell types, and 11% were induced in most (5–7) cell 
types (Fig.  9a; Additional file  1: Table  S8). Only 9 genes 
were induced in every context and these included STAT1 
and IRF1, in line with their apical role in IFNγ signaling.
We assessed the relationship between broad respon-
siveness, degree of induction, and STAT1/IRF1 bind-
ing. HeLa ChIP-chip data provided STAT1 and IRF1 
binding information for 24 es-indISGs present in all 7 
expression array datasets. Of these, 3/24 were induced 
exclusively in HeLa, 10/24 were induced in 2–4 lines and 
11/24 were induced in 5–7 lines (Fig. 9b). Of note, genes 
induced exclusively in HeLa were up-regulated to a much 
lower extent than ubiquitously IFNγ-responsive targets 
(Fig.  9c). Greater induction of ubiquitously responsive 
loci was paralleled by a higher density of TF binding 
at promoter proximal sites (Fig.  9d). Thus, the level of 
induction is linked to the degree of STAT1 and IRF1 
recruitment, and there is an unexpected link between 
the strength of ISG induction in one context (HeLa in 
this case) and competency to respond to IFNγ in other 
contexts.
SNPs modulate STAT1 and IRF1 binding in vitro
Defects in IFNγ signaling are linked to a wide range of 
disorders [40–44]. Several studies focused on the associa-
tion between genetic variants and the risk of IFNγ related 
disorders, but at gene promoters or coding regions of 
ISGs rather than IFNγ responsive enhancers. Within 
the 16 Mb of DNA around ISGs studied here, there are 
a total of 7.1 × 105 dbSNPs [hg19; SNPs (141)]. Of these, 
6648 dbSNPs lay within the 230 STAT1/IRF1 peaks. Only 
7 of these 6648 dbSNPs were listed on the GWAS data-
base. GWAS SNPs do not define all disease associated 
SNPs (DA-SNPs) because GWAS genotyping arrays pro-
vide low genomic coverage [45] and therefore the 6648 
dbSNPs may encompass other DA-SNPs not mapped yet. 
None of the 7 DA-SNPs (GWAS database) overlapped 
with a STAT1/IRF1 motif, but 80 of the 6648 dbSNPs 
overlapped with 27 STAT1 and 47 IRF1 motifs (Addi-
tional file 1: Table S9).



























































Fig. 7 STAT1 and IRF1 binding correlates with binding motifs. a Percent distribution of isolated STAT1 or IRF1 or dual STAT1 + IRF1 binding at proxi‑
mal (≤5 kb) or remote (>5 kb) sites of Known gene promoters. b TF binding sites were classified into 6 subclasses, then mapped motifs using CisGe‑
nome’s “Known Motif Mapping” program (see “Methods” section for details). Sets of equal numbers of randomly generated “peaks” were used to 
define the background occurrence of STAT1 and IRF1 motifs. Asterisk indicates significant difference between true and random peaks (p < 0.00005, 
two‑sided probability test in R). c Ratio of STAT1/IRF1 motifs at different categories of peaks
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We studied which of these 80 SNPs affect STAT1/
IRF1 binding. First, we utilized the CisGenome “Known 
Motif Mapping” program to predict which of the vari-
ants may modulate STAT1/IRF1 binding motifs (see 
“Methods” section). CisGenome compares the position 
weight matrix (PWM) in the JASPAR CORE database 
and creates likelihood scores for the reference or variant 
allele. We calculated the fold change in likelihood scores 
(variant/reference allele) to assess the predicted relative 
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Fig. 8 STAT/IRF1 recruitment at es‑indISGs vs res‑ISGs. a Map of isolated and dual STAT1 and IRF1 binding ± 100 kb of the TSS of es‑indISGs (top) 
and resISGs (bottom), after removing CIITA targets, in HeLa cells treated for 6 h with IFNγ. Red arrow indicated TSS and direction of transcription. 
Genes are ranked according to fold induction, indicated in brackets. b Histograms show the percentage of es‑indISGs or resISGs with proximal 
(≤5 kb) or distal (>5 kb) binding of STAT1 and/or IRF1. Asterisk p < 0.05, Fisher exact test. c Average number of TF binding events at proximal and 
remote sites at resISGs or es‑indISGs. Error bar: SEM; Asterisk p < 0.05, ANOVA followed by Fisher test
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dbSNPs were predicted to modulate the binding affinity 
of 24 IRF1 motifs and 10 STAT1 motifs (Additional file 1: 
Table S9).
To test these predictions in  vitro, we developed an 
ELISA-based DNA affinity assay (see “Methods” section). 
Canonical STAT1 or IRF1 motif-containing biotinylated 
33-mers were immobilized on streptavidin-coated 
96-well plates. Cell lysates from HeLa cells exposed 
to IFNγ for 6  h were mixed with either no or various 
amounts of Wt (positive control), mutated (negative con-
trol), or dbSNP (test) competitor probes, then added to 
the immobilized biotinylated probe, and the amount of 
bound TF determined using anti-STAT1 or anti-IRF1 
antibody. We tested 4 or 1 SNPs affecting IRF1 or STAT1 
sites, respectively (Fig.  10; Additional file  1: Tables  S9, 
S10). Wt IRF1 and STAT1 probes exhibited strong bind-
ing with low IC50s of 9.6 ±  1.5 or 4.2 ±  0.9  pmol/well, 
respectively, whereas control mutated probes had mini-
mal/no effect (Fig.  10; Additional file  1: Table  S10). 
3/6 of the IRF1 SNPs decreased affinity (rs365393, 
rs9262216, rs34494346) and 1/6 created a strong IRF1 










































































Fig. 9 Link between ISG responsiveness in HeLa cells, responsiveness in other cell types, and STAT1/IRF1 binding. a Percentage of ubiquitous (Ub), 
partially shared (pSh), or exclusive (Ex) human ISGs based on their responsiveness to IFNγ in the indicated number of cell lines. b Percentage of HeLa 
es‑indISGs which respond in only HeLa or in more cell types (as in a). For full lists of ISGs and es‑indISGs see Additional file 1: Tables S7, S8. c Level 
to which Ub, pSh or Ex es‑indISGs are induced in HeLa cells. d Average number of TF binding at promoter (≤5 kb) and remote (>5 kb) sites of the 
indicated types of es‑indISGs. Error bar indicates SEM; Asterisk p < 0.05, ANOVA followed by Fisher test










































































Fig. 10 SNPs modulate STAT1 and IRF1 binding in vitro. a IRF1, and: b STAT1 binding assays. Graphs show STAT1 and IRF1 binding signal to immo‑
bilized probes in the presence of different concentrations of competitor probes with either the variant or reference allele. 100% binding is that 
obtained in the absence of competitor. Arrows highlight the affected base (or 4 bases in the control mutated probe). As indicated, rs9260102 was 
also assessed in vivo (Fig. 11)
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single STAT1 SNP that we tested created a putative bind-
ing site, and indeed the T allele of rs2071790 showed high 
affinity binding (Fig.  10b; Additional file  1: Table  S10). 
Our ChIP-chip data indicated that this SNP lies within 
an isolated remote IRF1 peak, suggesting that the T allele 
would convert this regulatory element to a dual STAT1/
IRF1 enhancer. In summary, these data show close con-
cordance between the predicted and actual effects of 
SNPs on STAT1 and IRF1 binding. Thus, it is likely that 
most of the 34 predicted functional SNPs do in fact alter 
binding.
rs9260102 affects IRF1 binding in vivo
Next we asked if the T allele of rs9260102, which cre-
ates an IRF1 site in vitro (Fig. 10a), has this effect in vivo. 
This SNP lies ~1 kb upstream of the HLA-A locus, within 
an IFNγ-responsive IRF1 ChIP-chip peak in HeLa cells 
(Fig. 11a). To test whether it affects IRF1 binding in vivo 
we employed the EBV-transformed lymphoblastic cell 
line GM18857, which is heterozygous for rs9260102 
(G/T), implying that IRF1 should only bind to one (the 
T) allele. Treatment with IFNγ for 6 h induced a 1.8-fold 
increase in the total IRF1 ChIP-qPCR signal (Fig.  11b). 
Snapshot sequencing revealed that this IFNγ-dependent 
increase was due solely to elevated binding to the T allele 
(Fig.  11c). Thus, in silico prediction, an in  vitro binding 
assay, and in vivo allele specific ChIP all show that the G 
to T switch creates an IRF1 binding site (Fig. 10a; Addi-
tional file 1: Table S10).
Discussion
STAT1 and IRF1 drive the induction of IFN induced 
genes, but the extent to which they act collectively is 
















































































Fig. 11 rs9260102 modulates IRF1 binding in vivo. a Chromosomal location of rs9260102 and the alleles (strong IRF1 binding in bold), and a 
genome browser view of the SNP, which lies upstream of HLA‑A and within an IFNγ‑induced IRF1 Chip‑chip peak in HeLa cells. b ChIP‑qPCR of basal 
and IFNγ‑induced IRF1 recruitment at rs9260102 in GM18857 EBV transformed lymphocytes. c Electropherogram on left shows snapshot sequenc‑
ing of ChIP DNA, with peak quantification plotted on the right (mean ± range, n = 2)
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occurs together with IRF1, but most IRF1 binding (72%) 
is isolated (Fig. 7a). Binding occurs where there are cog-
nate binding motifs (Fig.  7), suggesting that most ChIP 
signals reflect direct recruitment. Both proximal and 
remote STAT1 and IRF1 binding is observed at robustly 
induced ISGs, but not at other loci (Fig.  6). In line with 
the importance of TF occupancy for responsiveness [46], 
every responsive locus exhibits a mixture of STAT1 and 
IRF1 bound enhancers (Fig.  8a). Moreover, dual bound 
enhancers distinguish induced vs resistant ISGs, whereas 
single bound enhancers are found with similar frequency 
at responsive or non-responsive ISGs (Fig. 8). This is not 
to say, however, that single bound enhancers are irrele-
vant. For example, while multiple remote SOCS1 enhanc-
ers recruit both TFs, the +50 kb element or promoter are 
targeted only by STAT1 or IRF1, respectively, yet both are 
involved in 3D looping (Figs.  4, 5). Similarly, while dual 
STAT1/IRF1 binding occurs at the active CIITA promoter, 
the −50 kb and +59 kb enhancers recruit only STAT1 or 
IRF1, respectively, yet contribute to 3D looping and are 
essential for responsiveness [7]. Indeed, all the responsive 
genes we surveyed exhibit a mix of STAT1-only, IRF1-
only, and STAT1/IRF1 dual enhancers (Fig. 8). Together, 
these results suggest that IFNγ-responsiveness requires 
cooperation between enhancers that bind both or either 
TF, but that STAT1- or IRF1-only enhancers are insuf-
ficient for gene induction. Irrespective, it is clear that 
responsive ISGs integrate information from both STAT1 
and IRF1.
Previously, we showed that there is a pre-existing 3D 
structure at the silent CIITA locus, generated through 
looping between enhancers that subsequently recruit 
STAT1 and IRF1 upon IFNγ treatment [7]. This was true 
even in the absence of BRG1, a chromatin remodeling 
enzyme that is critical to allow stable TF recruitment 
and thus IFNγ-responsiveness. Subsequent genome-wide 
analyses indicate that enhancer looping in the poised but 
silent state is common at inducible loci [47]. We observed 
the same phenomenon at the IFNγ responsive SOCS1 
locus (Fig. 5). Potentially, these contacts are mediated by 
pioneer factors that mark responsive enhancers, but their 
identity at ISGs is unknown. The data here and other 
studies show that STAT1 and IRF1 can bind some sites 
in the basal state [21, 28], so in theory, low/unstable bind-
ing (undetectable by ChIP) could poise ISG enhancers. It 
would thus be interesting to perform looping studies at 
ISGs in STAT1/IRF1 deficient cells. It is of note that the 
degree to which ISGs were induced in HeLa cells pre-
dicted whether they were likely to respond to IFNγ in 
other cells (Fig. 9). Thus, the chromatin at these genes is 
accessible in many contexts. The factors that mediate this 
broad poised, open state may also initiate the basal loop-
ing at ISGs.
Over 90% of the disease markers identified in GWAS 
studies lie within the non-protein-coding regions of the 
genome [48]. These markers correlate with gene expres-
sion [49–52], and lie within gene regulatory regions 
[53–56]. There is thus considerable interest in identify-
ing SNPs that influence TF binding and, therefore, gene 
regulation. We identified 80 SNPs within STAT1 or IRF1 
motifs, and in silico assessment predicted that 34 may 
alter binding. In vitro quantification confirmed these pre-
dictions in 5/5 cases, arguing that most of/all the other 
predictions are accurate. The availability of a cell line het-
erozygous for one such SNP allowed us to test whether 
the prediction held up in  vivo. Indeed, the T allele of 
rs9260102, which lies just upstream of the HLA-A locus, 
bound IRF1 whereas the G allele did not, as observed in 
silico and in vitro. These data serve as proof of principle 
that in silico prediction is a reliable tool to anticipate the 
effect of SNPs on STAT1 and IRF1 binding.
Conclusions
This study provides strong evidence for widespread coop-
eration between STAT1 and IRF1 at ISGs, and suggests 
that in silico predictions reliably predict the effect of 
nucleotide variants on binding in vivo.
Methods
Custom oligonucleotide ChIP Tiling array design
A custom oligonucleotide tiling array was designed to 
cover 11 genomic regions spanning a total of 16  Mb of 
human genomic DNA in 8 chromosomes (Additional 
file 1: Table S1). Regions covered from 1 to 5 Mb genomic 
sequences. Arrays consisted of 50 mers, in quadruplicate, 
with median probe spacing of 80  bp within non-repeti-
tive DNA regions.
ChIP on tiled genome arrays (ChIP‑chip) and ChIP–
quantitative PCR
Details of primers and antibodies used in ChIP assays are 
in Additional file  1: Tables  S11, S12. HeLa-ini1-11 cells 
(HeLa), were grown as described [12]. Cells were left 
untreated or exposed to 300 units/ml of human IFN-γ for 
6  h (PHC4834, BioSource International, Camarillo, CA, 
USA). Crosslinked chromatin was sonicated to an aver-
age size of about 500 base pairs and was incubated with 
STAT1 or IRF1 antibody. Bound fragments were puri-
fied by ChIP and amplified by ligation-mediated PCR, as 
described [7], then labeled and hybridized to the arrays. 
Hybridization intensities were normalized to internal 
standards and values from quadruplicate spots were aver-
aged. Significantly different intensities between ChIP 
DNA and input DNA samples in three biological rep-
licates (p < 0.0001) were determined with the Wilcoxon 
rank-sum test. Peaks representing significantly enriched 
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DNA regions (p  <  0.0001) where the ratio of ChIP to 
input DNA was 1.5-fold or more were visualized with 
the University of California at Santa Cruz Human (Homo 
sapiens) Genome Browser (Phast-Cons) and are plotted 
on a log2 scale. Peaks in a sliding window of 500 base 
pairs were merged with an in-house Perl script pipeline. 
ChIP—quantitative PCR was done as described [7], and 
in all cases, the low background signal obtained with a 
no-antibody control was subtracted.
Custom oligonucleotide ChIP tiling array data analysis
Raw intensities from three independent biological repli-
cates, quality assessed by Nimbelgen SignalMap software, 
were quantile normalized [57], and averaged for each 
quadruplicate 50 mer. We developed a Wilcoxon Rank 
Sum test [58] based software to studying the difference 
between the intensities of the ChIP signal compared to the 
input DNA signal for each probe within a 500 bp sliding 
window. Genomic positions with statistically higher inten-
sities (>1.5-fold, p < 10−4) from input DNA were merged 
to form a peak. ChIP-chip data were imported into UCSC 
genome browser (assembly hg17, NCBI build 35) as two 
sets of separate tracks for each antibody before and 6  h 
after IFNγ treatment (http://research.lunenfeld.ca/IFNy).
STAT1 and IRF1 motif analysis
We mapped STAT1 and IRF1 consensus motifs to the 
STAT1 and IRF1 ChIP-chip binding regions by using 
CisGenome “Known Motif Mapping” program. Motif 
occurrences were determined by using position frequency 
matrices (PFMs) of STAT1 (ID: MA0137.2) and IRF1 (ID: 
MA0050.1) from the JASPAR CORE database. The PFMs 
were converted to pseudo-count matrix for CisGenome’s 
input. A motif mapping location is selected by the cut-
off of a likelihood ratio (LR) > 500. The LR is determined 
by comparing the motif ’s PFM with a background model 
estimated from input ChIP-chip regions in the 3rd order. 
Seven sets of ChIP-chip peak regions were mapped and 
compared with background control regions: STAT1 peaks 
(92), IRF1 peaks (196), merged STAT1 and/or IRF1 peaks 
(231), dual STAT1 and IRF1 peaks (56), STAT1 peaks iso-
lated from IRF1 peaks (isolated-STAT1, 56), IRF1 peaks 
isolated from STAT1 peaks (isolated-IRF1, 140), and basal 
IRF1 peaks. For each set of peaks, the same number and 
size of control background regions were randomly sam-
pled from blank regions without any ChIP-chip bind-
ings following the same frequency distribution as the real 
binding peaks within each cluster segments on the chro-
mosome of ChIP-chip data. The frequencies of regions 
mapped with motifs were compared between ChIP-chip 
peaks and random control sites by using the two-sided 
probability test in R for each paired set of peaks.
RNA extraction, expression microarray analysis, 
and Reverse transcriptase‑qPCR
RNA extraction and reverse transcription were done 
from HeLa cells left untreated or at 6, 24 or 48  h after 
IFNγ treatment as described previously [12]. RNA qual-
ity was checked using both Nanodrop (Thermo Fischer 
Scientific; 260/280 ratio was ≥1.8) and Bioanalyzer (Agi-
lent Inc.; RNA Integrity Number, RIN, ≥ 9.4, range 9.4–
9.9). RNA samples were converted to cDNA, followed by 
a second strand synthesis, and cRNA was prepared using 
the Ambion kit (Applied Biosystems). The cRNA was col-
umn purified and quality was checked using Bioanalyzer 
(Agilent Inc.). A total of 1.5 µg of cRNA was hybridized 
to human whole-genome expression arrays (HumanRef-6 
Expression BeadChip, Illumina, Inc.) using standard 
Illumina protocols. Slides were scanned on an Illumina 
Beadstation and analyzed using BeadStudio (Illumina, 
Inc). Genes induced by ≥twofold compared to controls 
and that achieved a differential score of ≥13 were classi-
fied as strongly induced ISGs. ISGs which achieved a dif-
ferential score of ≥13 but fold induction less than 2 were 
considered weakly induced. Genes reduced by ≥twofold 
compared to control and achieved a differential score 
of ≤ −13 were considered strongly reduced. Genes that 
had a differential score of ≤ −13 but the fold reduction 
was less than 2 were considered weakly reduced. Three 
biological replicates were included for each treatment 
group.
RT-qPCR was performed much as described [59]. 
Briefly, RNA was extracted from HeLa cells left untreated 
or at 6, 24 or 48 h after IFNγ treatment using Trizol (Inv-
itrogen), and quality assessed by RIN and OD260/280 as 
above. cDNA was prepared from 1  mg RNA using ran-
dom primers and SuperScript RT (Invitrogen). Ampli-
fication of cDNA was performed  using gene specific 
primer pairs and SYBER Green Mix (ABI). PCR was ran 
on Applied Biosystems PRISM 7900HT. Primers were 
designed in the coding region of each gene (Additional 
file 1: Table S12). Human genomic DNA was used to pre-
pare calibrators for the quantification of cDNAs. Disso-
ciation curves were inspected to ensure a single product 
and all PCR products were also tested on a gel to con-
firm amplification  specificity. In addition,  no template 
controls (NTC) were included to ensure the absence of 
DNA contamination. Gene expression was normalized 
to multiple house-keeping/reference genes to control for 
the total amount of RNA. All experiments were done in 
triplicate.
Chromosome conformation capture (3C)
The 3C assay was conducted as described [7, 8]. Primer 
sequences are provided in Additional file 1: Table S12.
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Assessment of TF binding distribution around different 
classes of ISGs
We compared the distribution of TFBS in the vicinity 
of es-indISGs and resISGs in STAT1 peaks, IRF1 peaks, 
and merged STAT1 and IRF1 peaks. We first aligned the 
TFBS within a range of 400  kb region around the TSS 
of each gene in a 1 kb resolution, which means that we 
divided each region into 1 kb windows with the window 0 
centered at the TSS and others line up to the 200 kb end 
upstream and 200 kb end downstream, and then scored 
the frequency of TFBS at each window as the number 
of peaks whose center was within the window. If 400 kb 
extended beyond the ChIP-chip segments, the binding 
frequencies along the truncated regions were regarded 
as missing data. Then we plotted the average binding fre-
quencies per 1 kb window versus the relative distance of 
each to the TSS. Missing values were discarded for aver-
aging the frequencies.
Defining STAT1 and IRF1 functional SNPs
First, we queried dbSNPs located within the 230 ChIP-
chip peaks (UCSC, Build hg19; Track, All SNPs(141); 
Table, snp141). We defined a total of 6648 dbSNPs. Next 
we defined SNPs that overlap with STAT1 or IRF1 bind-
ing motifs within the 230 ChIP-chip peaks. Then we 
selected a region of ±50 bp around the SNPs that over-
lapped with STAT1/IRF1 binding motifs and recovered 
the DNA sequence of these regions using CisGenome. 
Then we computationally evaluated the binding affin-
ity of the reference or variant sequence using the likeli-
hood scores obtained from the Cisgenome “known motif 
mapping” program with the sequences as input to map 
the STAT1 and IRF1 motif matrix. In some cases the 
introduction of the variant SNP renders the motif uni-
dentifiable and in this case the sequence of the motif was 
indicated as “NULL” and the likelihood score was consid-
ered as zero (Additional file 1: Table S9). The cutoff value 
of affinity change was set at 1.5-fold.
ELISA‑based DNA binding affinity assay and ChIP coupled 
with DNA sequencing
We designed 33-mers with either the reference or variant 
alleles (Additional file 1: Table S13). Control probes with 
wild type or dead mutant STAT1 or IRF1 motifs were 
also included. Probes were ordered biotinylated or bio-
tin-free (competitors). Two pmol of biotinylated probes 
were immobilized per well of 96-well streptavidin-coated 
plates. Cell lysates where incubated with different con-
centrations of the competitor probes (probe-lysate mix) 
at 4  °C for 3  h to allow STAT1 or IRF1 binding. The 
probe-lysate mix was then added to streptavidin-coated 
plates with immobilized biotin probes and incubated 
overnight at 4  °C. To quantify bound TFs, wells were 
washed and probed with STAT1 or IRF1 primary anti-
bodies, followed by IR-800 conjugated secondary anti-
bodies. Excess antibodies were washed thoroughly and 
plates were scanned and quantified using Odyssey Infra-
red imaging system (LICOR). Signal from no-competitor 
well is considered as 100% and the % antibody signal was 
plotted against competitor probe concentration. IC50 
values were calculated using Graphpad PRISM 5.2.
For in  vivo studies, EBV-transformed lymphoblastic 
GM18857 cells, cultured as recommended by the sup-
plier (Coriell Biorepositories), were treated with IFNγ 
for 6 h, fixed and harvested for ChIP analysis. Chromatin 
was immunoprecipitated using IRF1 antibody and iso-
lated DNA was sequenced using Snapshot sequencing.
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